Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
NOGOB receptor–mediated RAS signaling pathway is a target for suppressing proliferating hemangioma
Wenquan Hu, Zhong Liu, Valerie Salato, Paula E. North, Joyce Bischoff, Suresh N. Kumar, Zhi Fang, Sujith Rajan, M. Mahmood Hussain, Qing R. Miao
Wenquan Hu, Zhong Liu, Valerie Salato, Paula E. North, Joyce Bischoff, Suresh N. Kumar, Zhi Fang, Sujith Rajan, M. Mahmood Hussain, Qing R. Miao
View: Text | PDF
Research Article Angiogenesis Vascular biology

NOGOB receptor–mediated RAS signaling pathway is a target for suppressing proliferating hemangioma

  • Text
  • PDF
Abstract

Infantile hemangioma is a vascular tumor characterized by the rapid growth of disorganized blood vessels followed by slow spontaneous involution. The underlying molecular mechanisms that regulate hemangioma proliferation and involution still are not well elucidated. Our previous studies reported that NOGOB receptor (NGBR), a transmembrane protein, is required for the translocation of prenylated RAS from the cytosol to the plasma membrane and promotes RAS activation. Here, we show that NGBR was highly expressed in the proliferating phase of infantile hemangioma, but its expression decreased in the involuting phase, suggesting that NGBR may have been involved in regulating the growth of proliferating hemangioma. Moreover, we demonstrate that NGBR knockdown in hemangioma stem cells (HemSCs) attenuated growth factor–stimulated RAS activation and diminished the migration and proliferation of HemSCs, which is consistent with the effects of RAS knockdown in HemSCs. In vivo differentiation assay further shows that NGBR knockdown inhibited blood vessel formation and adipocyte differentiation of HemSCs in immunodeficient mice. Our data suggest that NGBR served as a RAS modulator in controlling the growth and differentiation of HemSCs.

Authors

Wenquan Hu, Zhong Liu, Valerie Salato, Paula E. North, Joyce Bischoff, Suresh N. Kumar, Zhi Fang, Sujith Rajan, M. Mahmood Hussain, Qing R. Miao

×

Figure 6

NGBR knockdown attenuates growth factor–induced phosphorylation of AKT and ERK1/2 in HemSCs.

Options: View larger image (or click on image) Download as PowerPoint
NGBR knockdown attenuates growth factor–induced phosphorylation of AKT a...
Protein levels were determined by Western blot. NGBR knockdown reduced the FGF2-induced (A), VEGF-induced (B), and EGF-induced (C) phosphorylation of AKT and ERK1/2 in HemSCs. Twenty-four hours after siControl or siNGBR transfection, cells were arrested overnight in serum-free medium and then stimulated with FGF2 (100 ng/mL), VEGF (100 ng/mL), and EGF (100 ng/mL) in serum-free medium at indicated times (5, 10, 20, and 30 minutes). The growth factor–induced phosphorylation AKT and ERK1/2 were determined by Western blot. Total AKT, total ERK1/2, and actin protein levels were used as respective loading controls. Quantitative analysis of phosphorylated proteins was carried out using ImageJ software, and proteins were normalized to total proteins correspondingly. *P < 0.05 vs. control (siControl) cells. #P < 0.05 vs. control (siControl) cells treated by FGF2, VEGF, and EGF (n = 3), 3 repeats. Statistical analyses: 1-way ANOVA with Bonferroni’s post hoc test; data are expressed as mean ± SEM. NGBR, NOGOB receptor; HemSCs, hemangioma stem cells; siControl, control siRNA; siNGBR, NGBR siRNA.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts